Sandy Macrae - 01 Apr 2026 Form 4 Insider Report for SANGAMO THERAPEUTICS, INC (SGMO)

Reporting relationship: PRESIDENT, CEO AND DIRECTOR, Director
Issuer ticker: SGMO
Reported as of: 01 Apr 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 03 Apr 2026, 16:15:15 UTC
Prior SEC filing: 26 Feb 2026
Next SEC filing: 27 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Scott Willoughby, Attorney-in-Fact

Key filing fact

Sandy Macrae filed Form 4 for SANGAMO THERAPEUTICS, INC (SGMO) on 03 Apr 2026.

Key facts

This page summarizes Sandy Macrae's Form 4 filing for SANGAMO THERAPEUTICS, INC (SGMO).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 03 Apr 2026, 16:15.

Change

Previous filing in this sequence was filed on 26 Feb 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001675687 Primary reporting owner

Macrae Sandy

Relationship: PRESIDENT, CEO AND DIRECTOR, Director
Address: C/O SANGAMO THERAPEUTICS, INC., 501 CANAL BLVD., RICHMOND
Signature: /s/ Scott Willoughby, Attorney-in-Fact
Signature date: 03 Apr 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SGMO transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +2,500,000
Change %
Price: $0.000000^*
Shares after: 2,500,000
Date: 01 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 2,500,000
Exercise price: $0.2601
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

One-quarter (1/4) of the shares subject to the option will vest and become exercisable on the first anniversary of the grant date, and the remainder of the shares will vest and become exercisable in 24 successive equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.